AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04628026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
Study NCT04628026 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients >60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients >60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are >60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients >60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment.
Study NCT04628026 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard chemotherapy
Description: Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients >60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients >60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are >60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients >60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment.
Study NCT04628026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Description: Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
Study NCT04628026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autologous stem cell transplantation
Description: Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
Study NCT04628026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
Study NCT04628026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic stem cell transplantation
Description: Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
Study NCT04148417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo+ Tympanostomy Tube Device
Description: The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
Study NCT05333458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT06254625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiome
Description: Fecal microbiome transplantation from a healthy donor.
Study NCT06254625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Place capsules
Study NCT04890184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grape juice
Description: grape juice
Study NCT04890184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention
Study NCT05557708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 212-Lead Pentixather
Description: Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
Study NCT05557708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 203-Lead Pentixather SPECT/CT
Description: Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
Study NCT04708522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Control - Equal Breathing Technique
Description: The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
Study NCT04708522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Mindfulness Exercise
Description: The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
Study NCT04708522 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
Study NCT06397846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample
Description: blood sample will be collected at baseline
Study NCT06004479 — intervention group
Intervention type: OTHER
Intervention: Carotenoid Intake
Description: Carotenoid intake assess by 24 hour dietary recalls
Study NCT06004479 — intervention group
Intervention type: OTHER
Intervention: Serum carotenoid concentration
Description: Serum total carotenoid concentration
Study NCT04628013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noxious Electrical Stimulation (NxES)
Description: The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
Study NCT05729217 — intervention group
Intervention type: OTHER
Intervention: SBQ-LC survey
Description: Symptom burden questionnaires of Long COVID
Study NCT05903196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mygen V-1000 RF system
Description: The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
Study NCT06457984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium nutritional supplementation
Description: Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
Study NCT06457984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium nutritional supplementation
Description: Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
Study NCT05236491 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: Participants are to receive a booster dose of a COVID-19 vaccine.
Study NCT05586113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-day Tegoprazan bismuth-containing quadruple therapy
Description: 10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
Study NCT05586113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-day Tegoprazan bismuth-containing quadruple therapy
Description: 10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
Study NCT05483387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with HBS 2 Resorb Mg
Description: Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
Study NCT03643042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
Study NCT05946070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONKOSIS
Description: ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
Study NCT05713266 — intervention group
Intervention type: DEVICE
Intervention: MouthLabTM
Description: Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
Study NCT04769869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study NCT05128019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICIT
Description: Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
Study NCT05582057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths to Grow: Preteen
Description: An online, strength based parenting program for parents of preteens (aged 9-14).
Study NCT05407142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS
Description: Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml.
Study NCT05407142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The data from volunteers from the control group
Description: Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
Study NCT05207137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone call about vaccination
Description: Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
Study NCT05303935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 50 MG
Description: A single dose of 50mg of quetiapine taken at bedtime for one night.
Study NCT05303935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
Study NCT05276505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy Tablet
Description: Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
Study NCT06457620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
Study NCT06457620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Physical Preatment
Description: Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
Study NCT05442203 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zio Patch Monitor
Description: Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
Study NCT05442203 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiogram
Description: Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
Study NCT04769869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD4604 for inhalation via DPI
Description: Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10.
Study NCT04769869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for IV administration
Description: Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study NCT04769869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for oral administration
Description: Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study NCT04769869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4604 for inhalation via DPI
Description: Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
Study NCT06142188 — intervention group
Intervention type: BIOLOGICAL
Intervention: Relmacabtagene Autoleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Study NCT04862962 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
Description: Oral Tablets 10 mg/10 mg or 20 mg/10 mg
Study NCT05430841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG, 18F-AlF-FAPI PET/CT
Description: Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
Study NCT04953650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
Study NCT04953650 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
Study NCT05177952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Resistance training with BFR
Study NCT05177952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Resistance Training with no BFR
Study NCT06121700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy targeted to the primary lesion
Description: 5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
Study NCT06121700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy targeted to the metastatic lesions
Description: Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
Study NCT06121700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W.
Study NCT06121700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.